Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 1 of 116. PageID #: 237607

HIGHLY CONFIDENTIAL

SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

VIDEOTAPED DEPOSITION OF

BARBARA MARTIN

January 25, 2019

Chicago, Illinois

GOLKOW LITIGATION SERVICES 877.370.3377 ph | 917.591.5672 fax deps@golkow.com

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 2 of 116. PageID #: 237608 Highly Confidential - Subject to Further Confidentiality Review | |
|---|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| REDACTED | to Further Confidentiality | Review |
|----------|----------------------------|--------|
| REDACTED | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 3 of 116. PageID #: 237609

| High. | ly Confidential - Sur | oject to Further Col | niidentiality keviev | V |
|----------|-----------------------|----------------------|----------------------|---|
| REDACTED | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 4 of 116. PageID #: 237610

| Ca | ase: 1 | L:17-m | d-0280 Highly | 4-DAP | Doc# dential | : 1981- - Subje | 7 Filed: ect to F | 07/24/ 3urther 0 | 19 5 of confiden | 116. Pa | ageID #: Review | 237611 | |
|-----|--------|--------|------------------|-------|-----------------|---------------------------|----------------------|-------------------------|---------------------|---------|--------------------|--------|--|
| RED |)A(| CTE | D | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

| Case: | 1:17-md-028 | 304-DAP Doc a | #: 1981-7 Filed | : 07/24/19 6 0 Further Confiden | f 116. PageID | #: 237612 |
|-------|-------------|------------------|------------------------|--|-----------------|------------------|
| REDA | CTED | ry communication | | de cher comme | relation review | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | 6 | (Pages 18 to 21) |

| Case: 1:17-md-02804-DAP Doc.#: 1981-7 Filed: 07/24/19 7 of 116. PageID #: 237613 Highly Confidential - Subject to Further Confidentiality Review REDACTED REDACTED |
|--|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 8 of 116. PageID #: 237614 Highly Confidential - Subject to Further Confidentiality Review |
|---|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 9 of 116. PageID #: 237615 Highly Confidential - Subject to Further Confidentiality Review | |
|---|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 9 (Pages 30 to 33) | |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 10 of 116. PageID #: 237616 Highly Confidential - Subject to Further Confidentiality Review REDACTED |
|---|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 10 (Pages 34 to 37) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 11 of 116. PageID #: 237617 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 11 (Pages 38 to 41) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 12 of 116. PageID #: 237618 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

| Case: 1:17-md-02804-DAP | Doc #: 19 | 81-7 Filed: | 07/24/19 | 13 of 116. | PageID #: 237619 | |
|-------------------------|-----------|-------------|----------|------------|------------------|--|
| REDACTED | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| Highly Confidential | Subject to Further | r Confidentiality Re | view |
|---------------------|--------------------|----------------------|---------------------|
| REDACTED | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | 14 (Pages 50 to 53) |
| | | | IT (Payes DU LO DJ) |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_14 of 116. PageID #: 237620

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 15 of 116. PageID #: 237621 Highly Confidential - Subject to Further Confidentiality Review | |
|---|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 15 (Pages 54 to 57) | |

REDACTED

18

19

20

21

22

23

24

sound.

role wasn't involved with determining what the

rules were. I was asked to determine if logic was

Q. My question was a little different. You

said, "I've heard bits and pieces over the years.

It's hard to pinpoint exactly when I learned

specific types of information."

Highly Confidential - Subject to Further Confidentiality Review

1 But the simple question I asked you was: 2 Do you ever recall being educated on what 3 Walgreens' responsibilities as a distributor were? 4 Yes or no. MR. SWANSON: Asked and answered. 5 6 BY THE WITNESS: 7 A. I relied on other people to make sure 8 that they knew that the -- Walgreens was following 9 the policies and procedures. BY MR. MOUGEY: 10 11 Q. So, the answer to my question is no, 12 correct? You can't recall ever being educated on 13 what Walgreens' responsibilities as a distributor 14 were, correct? 15 MR. SWANSON: Object to form, mischaracterizes 16 her testimony. 17 BY THE WITNESS: 18 A. If that's how you want to interpret what 19 I'm saying. 20 BY MR. MOUGEY: 21 Q. You have said repeatedly that you relied 22 on other people, and I don't know if by relying on 23 other people that you just reviewed the reports and 24 someone else implemented. What I'm asking you is a Page 59 Page 61 1 from the beginning, just cut it off at 2015, you 1 simple question, and I'm going to ask it for about 2 don't believe that the work you performed was to 2 the fourth or fifth time. 3 ensure that Walgreens was filling its role as a 3 Do you recall ever being educated about 4 distributor, correct? 4 what Walgreens' responsibilities were as a 5 5 A. My role at various times, I was asked to distributor? б look at reports, look at item movement and б MR. SWANSON: Asked and answered. 7 determine if the logic was sound. How that was 7 BY MR. MOUGEY: 8 8 being interpreted in regards to various O. Yes or no. 9 regulations, I honestly didn't know how that fit 9 MR. SWANSON: Asked and answered. 10 in. 10 BY THE WITNESS: 11 Q. And you can't recall ever being educated 11 A. Again, I was relying on other people to 12 on what Walgreens' responsibilities as a 12 determine what the regulations were. 13 distributor were? 13 BY MR. MOUGEY: 14 A. I'm sure I've heard different bits and 14 O. So, the answer is --15 pieces of things over the courses of years, but 15 A. Our legal. 16 it's hard to pinpoint exactly when I would have 16 Q. -- no, you've never been educated --17 learned what types of information. And, again, my 17 MR. MOUGEY: I am sick and tired of the head

have another camera? Get the camera off of me and let's put it on Walgreens counsel with the yeses

shaking on the yes and no from you two. I do not

I will tell you what. We are going to

take a break. Do we have an extra camera? Do we

24 and nos and the head shaking repeatedly in the

want yeses, nos, in answers.

Page 60

18

19

20

21

22

23

Highly Confidential - Subject to Further Confidentiality Review

Page 62 Page 64 peripheral sight of the witness. This has been MR. SWANSON: Asked and answered. 1 1 2 going on for two months with Kate over there 2 BY THE WITNESS: 3 3 shaking her head yes and no. A. Again, as far as regulations, I relied on our legal department to provide that guidance. 4 MR. SWANSON: You are not putting a camera on 4 5 BY MR. MOUGEY: 5 me. So, you can turn it off or keep it on you. б MR. MOUGEY: I do not want --6 Q. Did you -- did you -- were you trained 7 7 MR. SWANSON: Stop the speech. Ask questions. in any shape, form or fashion on Walgreens' 8 MR. MOUGEY: -- any more gestures. 8 responsibilities as a distributor? 9 There is no speech. I do not want any 9 A. Again, Walgreens' responsibilities, I more yes or no head shaking. It's the most left that up to other people to determine. 10 10 11 unprofessional. And your office has done this 11 Q. So, you didn't receive any training from repeatedly over and over again for two months. 12 anyone else about what Walgreens' responsibilities 12 13 MR. SWANSON: Are you done? 13 and duties were as a distributor? 14 MR. MOUGEY: Are you done? Are we done with 14 MR. SWANSON: Objection. 15 the head shaking? The witness is right there. 15 BY THE WITNESS: 16 MR. SWANSON: Do you need a breather? 16 A. It wasn't my area of responsibility to 17 MR. MOUGEY: The witness -- I don't need a 17 determine how to interpret rules and regulations. 18 breather. I need you to stop head shaking. 18 BY MR. MOUGEY: 19 MR. SWANSON: Then calm down. 19 Q. I understand that your -- you think it's 20 MR. MOUGEY: Don't tell me to calm down. 20 someone else. But all I'm simply asking is: Did 21 MR. SWANSON: And ask questions. 21 you get any training about what Walgreens' 22 22 MR. MOUGEY: I am sick and tired of Kate responsibilities were as a distributor? It's a 23 sitting there shaking her head in the direct 23 simple yes or no answer. 24 peripheral sight of the witness for answers. 24 And if it's no, it's okay. Just say no. Page 63 Page 65 1 THE WITNESS: I am not even looking at Kate. 1 If you didn't get any training about Walgreens' 2 MR. SWANSON: Nobody needs your speech, Peter. 2 responsibilities as a distributor, no is fine. 3 Go ahead. 3 A. I relied on other people to interpret 4 MR. MOUGEY: I don't need the head shaking. 4 the regulations. So, if you want to interpret that 5 5 Are you done with the head shaking? as a no, please do so. б MR. SWANSON: I'm not going to respond. б Q. I'm not trying to interpret. I want you 7 MR. MOUGEY: Are you done with the head 7 to tell me generally do you ever recall being 8 trained on Walgreens' responsibility as a 8 shaking? 9 MR. SWANSON: Do you want to go off the record 9 distributor? 10 and take a break or not? 10 A. And, again, my answer is it's not my 11 MR. MOUGEY: No, I don't need a break. 11 responsibility to interpret regulations. 12 MR. SWANSON: Then ask a question. 12 Q. So, I didn't use the word "regulations" 13 MR. MOUGEY: Are you done with the head 13 in my question. Okay. I have taken out "code." I've taken out "regulations." And I've used the 14 shaking? Yes or no. Are we done? 14 15 MR. SWANSON: Ask a question. 15 word "responsibilities." You understand the 16 difference, correct? MR. MOUGEY: I will take that as a yes, we're 16 17 done. And every time I get a head shake, I'm going 17 A. In this context, I'm not sure I do. Q. Okay. I'm not using the word 18 to announce it on the record. 18 19 "regulation." I'm not using the word "code." You MR. SWANSON: That's great. 19 20 MR. MOUGEY: That is great. 20 understand that, right? BY MR. MOUGEY: 21 A. You didn't use those words, yes, I 21 Q. Do you recall ever being educated on 22 22 understand that. 23 Walgreens' responsibility as a distributor during 23 Q. And when I use the word "training,"

at Walgreens, training was often done through

24

24

your tenure at Walgreens?

Page 66 Page 68 PowerPoints or memos, things along those lines. 1 1 A. I was trusting --2 You understand that, right? 2 MR. SWANSON: Object to form. 3 3 BY THE WITNESS: A. More toward to the stores. I don't A. -- our legal department to interpret the 4 remember being trained as a corporate employee 4 5 5 using PowerPoint presentations. responsibilities. 6 Q. So, you went to conferences and attended 6 BY MR. MOUGEY: 7 7 conferences, correct? Q. I understand. That's not the question 8 A. I was reminded that I attended one 8 about who you were relying on. I asked did Barbara 9 conference. 9 Martin have an understanding of what Walgreens' 10 Q. So, did you attend conferences or 10 responsibilities were as a distributor? Did you 11 meetings or continuing education or anything specifically, Barbara Martin, or were you relying 11 12 explaining what Walgreens' responsibilities were as 12 solely on other departments to fill that role? 13 a distributor? 13 A. I was relying on other departments to 14 14 fill that role, and as I've said over the course of A. I remember at some point. I don't 15 remember the date. It was brought up in 15 my years of experience, I've learned things. It's 16 discussions that I attended one seminar. It wasn't 16 hard to say what I learned when and when I learned 17 direct to Walgreens' roles and responsibilities. 17 it. So, if I learned something in '09, I can't 18 It was some company's presentation, and they were 18 recall if I learned it in '09, 2012 or two weeks 19 trying to sell their order patterns. 19 ago. 20 Q. That's the only time you remember any 20 Q. I didn't ask what year. I didn't ask 21 continuing education, seminar, explanation, about 21 what month. I didn't ask two weeks ago. What I've 22 22 what Walgreens' responsibilities as a distributor asked is: Does Barbara Martin have an 23 were, correct? 23 understanding of what Walgreens' responsibilities 24 That wasn't a continuing education 24 generally as a distributor are? Page 67 Page 69 1 1 seminar. I wish it would have been. I would have MR. SWANSON: Object to form, asked and 2 2 at least gotten some credit. answered. 3 Q. Right. But what I asked was: The only 3 BY THE WITNESS: A. And I've relied on other people to 4 time you remember any educational piece about what 4 5 5 interpret what those responsibilities were. I Walgreens' duties or responsibilities were as a б distributor was a third-party conference that was 6 could -- once they would tell us what the 7 trying to sell a product? Yes? 7 responsibilities were, I could then interpret that 8 A. Again, I wasn't there to interpret 8 into my job as to how to look at reports or 9 Walgreens' regulations or responsibilities. I went 9 something like that if that was needed. 10 more interested in to see what this company's logic 10 BY MR. MOUGEY: 11 was doing and how to compare it to ours. 11 Q. And where did you -- who told you what 12 Q. And I appreciate that that you weren't 12 Walgreens' responsibilities were as a distributor? 13 there to interpret. I know you're not a lawyer. 13 A. We would have been relying on our legal 14 We have gone through your resume. I didn't ask if 14 department, Dwayne Piñon and his team, to review 15 you were there to interpret. 15 guidance. 16 What I've asked was: Other than the one 16 MR. MOUGEY: Let's take a break. 17 seminar given by a third party, was there any 17 THE VIDEOGRAPHER: We are going off the record 18 18 instance generally where you were educated on at 10:15. 19 19 Walgreens' responsibilities as a distributor? (WHEREUPON, a recess was had 20 20 A. I relied on other people to interpret from 10:15 to 10:31 a.m.) 21 Walgreens' responsibilities. 21 THE VIDEOGRAPHER: We are back on the record 22 Q. So, you did not specifically have an 22 at 10:31. 23 understanding of what Walgreens' responsibilities 23 BY MR. MOUGEY: 24 24 were as a distributor, correct? Q. Ms. Martin, we are in '09, 2010 where

Page 70 Page 72 reports were being flagged on a weekly basis in 1 you are reviewing reports generated by Wayne 1 2 2 2009? Bancroft's algorithm. 3 3 In a general description, can you tell A. I don't remember. 4 me what other areas of responsibility you had with 4 O. Thousands? 5 5 Walgreens suspicious order monitoring? I wouldn't even want to take a guess. 6 A. At that time all I was really doing was 6 Sorry. 7 7 looking at these reports in regards to order Q. Is there anywhere at Walgreens where the 8 monitoring. I had a lot of other roles and 8 orders that were being flagged by Wayne Bancroft's 9 responsibility in inventory. 9 algorithm were kept? Q. How many hours a week on average in '09 10 A. I don't believe that data is stored 10 11 were you looking at these reports? 11 anywhere. A. One to three maybe. Q. So, a report would populate and it would 12 12 13 Q. And do you have an understanding of how 13 just disappear into the Internet? 14 many hours a week in '09 Marcie was looking at 14 A. The reports populated. They held for a 15 these reports? 15 period of time. I don't remember what that period 16 A. I do not. 16 of time is or was. I know that our algorithms and 17 How many reports would you look at 17 order of monitors and order of logic have been during the one to three hours a week? 18 evolved over the years; and with that, there would 18 19 A. It's difficult to quantify that. It 19 have been different types of reporting that would 20 would depend on how easy they were to look at. The 20 have replaced the stuff I was looking at. 21 one that we looked at, it's simple. 3 is smaller 21 Q. There were a batch of I'm going to say 22 22 20, 25 different individual pieces of paper printed than 5. 23 Q. Right. 23 like the document I put in front of you as 24 There were others that I might have had 24 Martin -- I believe it was 2. Page 71 Page 73 to have done a much deeper dive into. So, no set 1 Do you have an understanding of -- did 1 2 2 number. Depends on... you have a paper file of 20 or 25 of those reports 3 Q. Are we talking a dozen, 15? Are we 3 from Bancroft's algorithm? 4 talking 1,000? 4 A. I don't remember. I mean, I know I kept 5 A. Definitely not 1,000. 5 a sample of the reports. How many they were, I б Q. Are we talking several hundred? б don't remember. 7 A. Again, it's -- it's hard to quantify. 7 Q. Why did you keep a sample of the Could be anywhere between 10 to 75. I really don't 8 8 reports? 9 know. 9 A. I guess I just kept them just to see how our system evolved over the years. I'm not really 10 Q. How about less than 100, more than 10 a 10 week? Is that fair? Somewhere in that range? 11 11 sure why. 12 A. That sounds fine. 12 Q. Did you look at them in preparation for 13 Q. Did you and Marcie Ranick divide them up 13 today? 14 in any way that she looked at some and you looked A. There were a few that we looked at, yes. 14 at others? 15 15 Q. All right. So, we've gone through your 16 A. No. When she came down, we would spend 16 participation in Walgreens' suspicious order 17 time together going through things, and then I'm 17 monitoring policies up until 2009 I believe. Okay? 18 sure she was looking at stuff on her own. But I 18 Can you give me any more examples moving 19 don't know what she was doing. 19 forward in time of your different roles? 20 Q. How would you determine, I'm going to 20 A. In relationship to the order monitoring 21 call it a batch that you would look at, the 10 to process or my roles in general with inventory? 21 22 less than 100 you'd look at a week? 22 Q. Walgreens -- as far as your role is what

we're talking about, your role with reviewing

procedures and policies, reports for Walgreens

23

24

23

24

Randomly pulling up reports.

Do you have an understanding of how many

Page 74

Highly Confidential - Subject to Further Confidentiality Review

1 implementing its responsibilities as a distributor.

- A. I wasn't responsible for writing SOPs
- 3 for Walgreens. I know that I provided information
- 4 for guidance for the stores and how to look up
- 5 things, but I wasn't writing SOPs.
- 6 Q. Okay. And I'm -- I'm sorry. I don't
- 7 think I used the word "writing SOPs." So, just
 - we're getting -- going through --
- 9 A. Sorry. I misinterpreted what you said.
- 10 Q. General understanding. Seems to be a
- 11 little bit of a problem for the last two hours.
- So, generally your roles with Walgreens
- 13 and its suspicious order monitoring policies, what
- 14 are some of the roles you filled? That's what I'm
- asking you to describe to me.
- So, you didn't write the policies. We
- got that. You're not a lawyer. We got that.
- 18 You're not interpreting anything. I got that. You
- 19 can't remember any specific education or training
- 20 with Walgreens as a distributor.
- Just give me some general descriptions
- 22 of other duties you filled with Walgreens'
- 23 suspicious order monitoring policies.
- MR. SWANSON: Object to the lawyer testifying,

- 1 A. So, I would have been continuing to work
 - 2 with Marcie to help her review and understand these

Page 76

- 3 reports. I would also work with her when she came
- 4 down to look at the monthly and quarterly reports.
- 5 Again, we had talked previously about me
- 6 supplying data when it was requested regarding
- 7 purchases.
- 8 Q. So, you continued to work with Marcie
- 9 and help her review and understand the reports.
- 10 That's one topic, right?
- 11 A. Um-hmm.
- Q. You also worked with her when she came
- down to look at the monthly and quarterly reports,
- 14 correct?

17

20

Page 75

- 15 A. Right.
- Q. Kind of the same area, right?
 - And then supplying data or data when
- 18 asked, right?
- 19 A. Um-hmm.
 - Q. Is there any other roles Barbara Martin
- 21 filled until the end of 2015 in relation to
- 22 Walgreens' suspicious order monitoring policies and
- 23 procedures?
- A. It's hard to think of something right

Page 77

- but you can answer the question if you understand
- 2 it.

1

2

8

- 3 BY THE WITNESS:
- 4 A. What time frame are you talking about?
- 5 BY MR. MOUGEY:
- 6 Q. We are moving on from 2009. So, I think
- 7 we've captured everything up to 2009, correct?
- 8 A. To the best of my recollection.
- 9 Q. To the best of your recollection. So,
- 10 let's -- moving forward, give me some general
- 11 descriptions of your duties with Walgreens'
- 12 suspicious order monitoring policies and
- 13 procedures.
- 14 A. Again, what time -- we're looking at
- 15 2010 now?
- Q. I'm just -- you don't remember dates
- 17 specifically.
- 18 A. No, that's what I'm trying to --
- Q. I understand. I'm saying moving through
- 20 '09 and afterwards. I'm giving you a really broad
- 21 window for you to generally describe to me what
- 22 Barbara Martin did in relation to Walgreens'
- 23 suspicious order monitoring policies and
- 24 procedures.

- 1 off the top of my head. I'm sure I had
- 2 correspondence and communication with other team
- 3 members.

4

10

- Q. So, when we look at your resume,
- 5 Martin 1, the only entry I see on your entire
- 6 resume in relation to Walgreens' suspicious order
- 7 monitoring policies and procedures with regard to
- 8 its role as a distributor is that last entry,
- 9 "assisted in the creation of the control drug order
 - monitoring reports." Do you see anything else?
- 11 A. That's -- that's the one that talks
- 12 about order monitoring, yeah.
- 13 Q. Right.
- A. For potentially suspicious orders.
- Q. Anything else on your resume where
- 16 you're describing your, Barbara Martin's, roles or
- duties in relation to Walgreens' suspicious order
- 18 monitoring policies and procedures as a
- 19 distributor?
- 20 A. I -- I can't think of anything.
- Q. All right. So, let me just make sure if
 - I can get a general understanding of what you were
- 23 doing.
- You helped create the drug order

22

Page 78

Highly Confidential - Subject to Further Confidentiality Review

2

8

1 monitoring reports, correct? By "create," you

- 2 provided some input into the reports. Is that --
- 3 is that fair?
- 4 A. Yeah, I mean, I didn't design the
- 5 report, but I looked at the data that was generated
- 6 off of the reports.
 - Q. And you gave input on some of the data
 - that the reports were flagging. Is that fair?
- 9 A. Yes.
- 10 Q. All right. You pulled data kind of on
- an ad hoc basis when people would ask. Is that
- 12 fair?

7

8

- 13 A. Yes.
- 14 Q. All right. And you helped Nancy --
- 15 no -- Marcie Ranick interpret some of these reports
- and understand the flow within the inventory. Is
- 17 that fair?
- 18 A. Yes.
- 19 Q. All right. Am I kind of capturing your
- 20 recollection of what Barbara Martin did in relation
- 21 to Walgreens as a distributor in relation to its
- 22 suspicious order monitoring policies and
- 23 procedures?

1

7

13

A. Yeah, I mean, there might have been

- 1 corporate level, correct?
 - A. Um-hmm.
- Q. So, post-2004, would you describe to me
- 4 what, if any, roles you had assisting Walgreens
- 5 with its compliance in its role as a distributor?
- 6 I'm sorry. As a pharmacy.
- 7 A. I'm sorry. I'm struggling with how to
 - answer that question, because when I think of like
- 9 Walgreens as a pharmacy, I would think of each
- 10 individual pharmacy.
- Q. Fair enough. And if your answer is no,
- 12 I really didn't have jobs or duties in relation to
- 13 ensuring Walgreens was compliant in its role as a
- pharmacy, that was more at the pharmacy level, then
- 15 that's a fine answer.
- 16 I'm just trying to understand what
- 17 Barbara Martin did and didn't do. So, if that was
- 18 something that you didn't do, that's okay. I just
- 19 want to know so I can figure out what to do with
- 20 the rest of our time.
- 21 Did Barbara Martin have any jobs or
- 22 responsibilities or duties post-2004 where you were
- 23 helping Walgreens with its compliance, good faith
- 24 dispensing, as a pharmacy?

Page 79

4

Page 81

Page 80

- other things. Nothing comes to mind. And, again,
- 2 I was more store-facing than distribution.
- $\,$ Q. $\,$ Now, let me maybe make sure you and I $\,$
- 4 aren't talking past each other and the use of the
- 5 word "distributor" maybe is causing you some
- 6 questions about your answer.
 - So, if I were to change the question and
- 8 say describe to me your roles, Barbara Martin's
- 9 roles, at Walgreens in relation to Walgreens
- 10 filling its role as a pharmacy through, for
- 11 example, good faith dispensing. Did you have
- any -- did you have any duties in that respect?
 - A. I was aware of good faith dispensing.
- 14 It was something that I was taught back in pharmacy
- school. I practiced it when I was a pharmacist in
- 16 the stores. I wasn't involved with writing the
- Walgreens procedures for good faith dispensing, but
- 18 generally aware of them through my entire career
- 19 starting in school.
- Q. So, you were a pharmacist, both a
- 21 staff -- an intern, a staff pharmacist and a
- 22 pharmacy manager all the way up to 2004, correct?
- 23 A. Yes.
- Q. So, post-2004, when you were more at the

- 1 MR. SWANSON: Object to form.
- 2 BY THE WITNESS:
- 3 A. So, I mean, I wasn't really responsible
 - for interpreting the regulations. But what I did
- 5 focus on, again, we can go back to I was looking at
- 6 these reports and other data. You know, I'm sure I
- 7 had conversations with various groups. It's hard
- 8 to remember what I've done in the last 30 years.
- 9 But, again, these reports were a big job
- and then as we got out of these reports and the
- system got more sophisticated, I transitioned back
- 12 into other inventory supporting roles.
- 13 BY MR. MOUGEY:
- Q. But I think what you told me earlier
- 15 this morning is that you were pulling the data
- 16 pulls and you weren't reviewing those. You were
- simply giving the data you were asked to pull to
- 18 the field. Correct?
 - A. Correct.
- Q. So, let's partition that one aside.
- 21 Okay?

19

- So, the only reports that you were
- 23 looking at were the ones that you and Marcie were
- 24 looking at during the pilot phase. Is that fair?

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 22 of 116. PageID #: 237628 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 23 of 116. PageID #: 237629 Highly Confidential - Subject to Further Confidentiality Review | 9 |
|--|--------|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 23 (Pages 86 | to 89) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 24 o Highly Confidential - Subject to Further Confiden | f 116. PageID #: 237630 tiality Review |
|--|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| Case: 1:17-m | d-02804-DAP Highly Confidence | Doc #: 1981-7 ential - Subject | Filed: 07/24/19 | 9 25 of 116. Pa onfidentiality Re | geID #: 237631 |
|--------------|---------------------------------|-----------------------------------|-----------------|--------------------------------------|---------------------|
| REDACTE | D | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | 25 (Pages 94 to 97) |

| Highi | y Confidential - Sur | ject to further Co | nridentiality keview | • |
|----------|----------------------|--------------------|----------------------|---|
| REDACTED | | | | |
| REDACTED | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_26 of 116. PageID #: 237632

| Case: 1:17-md-02804-DAP Doc#: Highly Confidential | 1981-7 Filed: 07/24/19 - Subject to Further Co. | 27 of 116. PageID #: 237 | 7633 |
|---|---|--------------------------|------|
| REDACTED | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| REDACTED | to Further Confidentiality Review |
|----------|-----------------------------------|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | 28 (Pages 106 to 109) |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_28 of 116. PageID #: 237634

| Case: 1 | :17-md-028 | 04-DAP Doo | : #: 1981-7 Fial - Subject | Filed: 07/24/1 to Further C | 9 29 of 116. I | PageID #: 2370 Review | 335 |
|---------|------------|------------|----------------------------|-----------------------------|----------------|--------------------------|---------|
| REDAC | CTED | , | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | 29 (Pages 110 | to 113) |

| Case: 1:17-md-02804- | DAP Doc #: 1981-7 Confidential - Subjection | Filed: 07/24/19 30 ect to Further Confidence | O of 116. PageID #: dentiality Review | 237636 |
|----------------------|--|--|---------------------------------------|---------------|
| REDACTED | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | s 114 to 117) |

| | Case: 1:1 | .7-md-028 | 04-DAP | Ooc #: 1981- | 7 Filed: | 07/24/19 3 | 31 of 116. | PageID #: 2 | 37637 |
|---|-------------|-----------|------------|-------------------------------|----------|------------|---------------------|-------------|-------------|
| R | EDAC | TED | TV Com Tuc | Ooc #: 1981- ential - Subj | | TURE CORE | TO CHILL PART I I V | T(CVTCW | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | 71 (Dagas | 110 +0 121) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 32 of 116. PageID #: 237638 Highly Confidential - Subject to Further Confidentiality Review | |
|--|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 32 (Pages 122 to 125) | |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 33 of 116. PageID #: 237639 Highly Confidential - Subject to Further Confidentiality Review | |
|--|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 33 (Pages 126 to 129) | |

| Case: 1:17-mo | d-02804-DA Highly Co | AP Doc#: 1 nfidential | 1981-7 Filed - Subject to | d: 07/24/19 Further Con: | 34 of 116. I | PageID #: 23 | 7640 |
|---------------|-------------------------|--------------------------|------------------------------|---------------------------|--------------|--------------|------|
| REDACTE | D | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| Case: 1:17-md | -02804-DAP Highly Confid | Doc #: 1981-7 | Filed: 07/24/1 | L9 35 of 116. Ponfidentiality 1 | ageID #: 23 | 37641 |
|---------------|-----------------------------|---------------|----------------|---------------------------------|-------------|-------------|
| REDACTE | D | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | 35 (Pages 1 | 134 to 137) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 36 of 116. PageID #: 237642 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 36 (Pages 138 to 141) |

| C | Case: 1:1 | . <mark>7-md-</mark> 0 | 0 <mark>2804-</mark> 1 | DAP D | OC #: 1 | 981-7 | Filed: | 07/24/1 urther C | 9 37 of | 116. P | ageID #: | 237643 | |
|----|-----------|------------------------|------------------------|-------|---------|-------|--------|-------------------------|---------|--------|----------|--------|--|
| RE | DAC' | TED |) | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

| Case: 1:17-md | -02804-DAP Do | oc #: 1981-7 Filed | d: 07/24/19 38 of 3 Further Confident | 116. PageID #: 2 | :37644 |
|---------------|---------------|--------------------|--|------------------|-------------|
| REDACTE | D | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | 38 (Pages | 146 to 149) |

| Highly Conf | ildential - Subject t | o Further Confidentialit | y Keview |
|-------------|-----------------------|--------------------------|-----------------------|
| REDACTED | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | 39 (Pages 150 to 153) |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_39_of 116. PageID #: 237645

| Case: 1:17-md-02804-DAF | P Doc #: 1981-7 Fidential - Subject | iled: 07/24/19 40 of to Further Confident | 116. PageID #: 23 | 37646 |
|-------------------------|-------------------------------------|--|-------------------|-------|
| REDACTED | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| | Case: 1:17 | -md-02804- Highly (| DAP Doc#: Confidential | 1981-7 Filed: - Subject to F | 07/24/19 41 Gurther Confide | of 116. Pagell entiality Revie | D #: 237647 w |
|---|------------|------------------------|------------------------|---------------------------------|------------------------------------|-----------------------------------|------------------|
| R | REDACT | TED | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| ı | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| Case: 1:17-mo | d-02804-DAP Do | oc #: 1981-7 Fil | ed: 07/24/19 42 | of 116. PageID # entiality Review | 237648 |
|---------------|----------------|------------------|-----------------|--------------------------------------|-----------------|
| REDACTE | D | | | 4 | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | ges 162 to 165) |

| Highly | Confidential - Subject | to Further Confidentiality | Review |
|-----------|------------------------|----------------------------|-----------------------|
| REDACTED | | to Further Confidentiality | |
| REDITETED | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | 43 (Pages 166 to 169) |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_43 of 116. PageID #: 237649

| | Highly Confidential | - Subject to | Further | Confidentiality | Review |
|----------|---------------------|--------------|---------|-----------------|-----------------------|
| REDACTED | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | 44 (Pages 170 to 173) |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_44 of 116. PageID #: 237650

| Case: 1: | 17-md- | 02804- Highly | DAP [Confide | Doc #: ential | 1981-7 - Subje | Filed: | 07/24/ Surther | 19 45 (Confide | of 116. ntiality | PageID Review | #: 23765 | 51 |
|----------|--------|-------------------------|--------------|---------------|-----------------------|--------|-----------------------|--------------------|---------------------|---------------|----------|----|
| REDAC | TED | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 46 of 116. PageID #: 237652 Highly Confidential - Subject to Further Confidentiality Review | |
|---|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| | Highly Confidential | - Subject to Further | Confidentiality | Review |
|----------|---------------------|----------------------|-----------------|--------|
| REDACTED | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_47 of 116. PageID #: 237653

| Highl | y Confidential - Subject | to Further Confidentialit | y Review |
|----------|--------------------------|---------------------------|----------|
| REDACTED | | to Further Confidentialit | |
| REDACTED | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_48 of 116. PageID #: 237654

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 49 of 116. PageID #: 237655 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 49 (Pages 190 to 193) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 50 of 116. PageID #: 237656 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 50 (Pages 194 to 197) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 51 of 116. PageID #: 237657 Highly Confidential - Subject to Further Confidentiality Review | |
|--|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 51 (Pages 198 to 201) | |

| | Highly | Confidential - | Subject | to Further | Confidentiality | Review |
|----------|--------|----------------|---------|------------|-----------------|--------|
| REDACTE | D | | | | | |
| REDITOTE | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_52 of 116. PageID #: 237658

| REDACTED | Review |
|----------|-----------------------|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | 53 (Pages 206 to 209) |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_53 of 116. PageID #: 237659

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 54 of 116. PageID #: 237660 Highly Confidential - Subject to Further Confidentiality Review |
|---|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 54 (Pages 210 to 213) |

| | Case: | 1:17-md | -02804-DAP | Doc #: 1981 | -7 Filed: O | 7/24/19 55 ther Confide | of 116. Pa | igeID #: 23766 eview | 61 |
|----|-------|---------|------------|-------------|-------------|----------------------------|------------|--------------------------------|---------|
| RF | EDA | CTE | D | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | 55 (Pages 214 | to 217) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 56 of 116. PageID #: 237662 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

| Case: 1:17-md-02804-DA Highly Cor | AP Doc #: 1981-7 | 7 Filed: 07/24/19 ect to Further Co | 9 57 of 116. Pa | ageID #: 2376 Review | 663 |
|--------------------------------------|------------------|-------------------------------------|------------------------|-------------------------|-----------|
| REDACTED | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | 57 (Pages 222 | 2 to 225) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 58 of 116. PageID #: 237664 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 58 (Pages 226 to 229) |

| Case: 1:17-md-02804-E | DAP Doc #: 1981-7 | Filed: 07/24/19 5 | 59 of 116. PageID | #: 237665 |
|-----------------------|-------------------|-------------------|-------------------|------------------|
| REDACTED | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | 59 (P | ages 230 to 233) |

| REDACTED | ial - Subject to Furt | ther Confidentiality | Review |
|----------|-----------------------|----------------------|-----------------------|
| REDACTED | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | 60 (Pages 234 to 237) |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_60 of 116. PageID #: 237666

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 61 of 116. Highly Confidential - Subject to Further Confidential | PageID #: 237667 |
|---|-----------------------|
| REDACTED | cy heview |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | 61 (Pages 238 to 241) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 62 of 116. PageID #: 237668 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 63 of 116. Fighly Confidential - Subject to Further Confidentiality | PageID #: 237669 |
|---|-----------------------|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | 63 (Pages 246 to 249) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 64 of 116. Fighly Confidential - Subject to Further Confidentiality | PageID #: 237670 Review |
|---|----------------------------|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | 64 (Pages 250 to 253) |

| (| Case: : | 1:17-md | -02804- Highly | DAP D | oc #: 19 | 9 <mark>81-7</mark> Subjec | Filed: t to Fu | 0 <mark>7/24/19</mark> rther Co | 9 65 of | 116. Pa | ageID #: Review | 237671 | |
|----|---------|---------|-------------------|-------|----------|-------------------------------|-------------------|------------------------------------|---------|---------|--------------------|--------|--|
| RE | DA | CTE | D | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

| Highly | y Confidential - Subject | to Further Confidentiality | Review |
|-----------|--------------------------|----------------------------|-----------------------|
| REDACTED | | to Further Confidentiality | |
| REDITOTED | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | 66 (Pages 258 to 261) |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_66 of 116. PageID #: 237672

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 67 of 116. PageID #: 237673 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 67 (Pages 262 to 265) |

| Case: 1:17-md-0 | 02804-DAP Doc#: | 1981-7 Filed: 07/ - Subject to Furth | <mark>/24/19 68 of 116. F</mark> ner Confidentiality | PageID #: 237674 Review |
|-----------------|-----------------|---|---|-------------------------|
| REDACTED | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | 68 (Pages 266 to 269) |

| | Case | : 1:17-mc | 1-02804- Highly | DAP Do | c#: 1981 | -7 Filed: | 07/24/19 urther Cor | 69 of 116 | . PageID# ty Review | 237675 | |
|---|------|-----------|--------------------|--------|----------|-----------|----------------------------|-----------|------------------------|--------|--|
| R | EDA | CTEI |) | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 70 of 116. PageID #: 237676 Highly Confidential - Subject to Further Confidentiality Review | |
|--|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 70 (Pages 274 to 277) | |

| Case: 1:17-m | nd-02804-DAP Do | c #: 1981-7 Filed: | 07/24/19 71 of 116 | . PageID #: 237677 ty Review | |
|--------------|-----------------|--------------------|--------------------|---------------------------------|-----|
| REDACTE | D | | | 0, 110, 101 | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | 71 (Pages 278 to 28 | 31) |

| C | Case: 1:1 | . <mark>7-md-0</mark> | 0 <mark>2804-</mark> Highly | DAP D | OC#: 1 | .981-7 Subjec | Filed: | 07/24/ 2urther (| <mark>L9 72 c</mark> | o <mark>f 116.</mark> ntiality | PageID Review | #: 23767 | 78 |
|----|-----------|-----------------------|--------------------------------|-------|--------|------------------|--------|-------------------------|----------------------|-----------------------------------|------------------|----------|----|
| RE | DAC' | TED | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

| | | Doc #: 1981-7 dential - Subje | Filed: 07/24/19 ect to Further Co | 9 73 of 116. Parameter Proposed in the proposed of the propo | ageID #: 237679 Review | |
|---------|---|----------------------------------|-----------------------------------|---|---------------------------|------|
| REDACTE | D | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | 73 (Pages 286 to | 289) |

| Case: 1:17-md-02804-DAP Doo | c#: 1981-7 Filed: ial - Subject to F | 07/24/19 74 of 116. Turther Confidentiality | PageID #: 237680 ty Review |
|-----------------------------|---|---|-------------------------------|
| REDACTED | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | 74 (Pages 290 to 293) |

| Case: 1:17-mo | d-02804-DAP D Highly Confide | OOC #: 1981-7 ntial - Subject | Filed: 07/24/19 t to Further Co | 75 of 116. Panfidentiality R | geID #: 237681 eview | |
|---------------|---------------------------------|------------------------------------|------------------------------------|------------------------------|-------------------------|--|
| REDACTE | D | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| REDACTED | - Subject to Further | Confidentiality Revie | W |
|----------|----------------------|-----------------------|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_76 of 116. PageID #: 237682

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 77 of 116. PageID #: 237683 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 77 (Pages 302 to 305) |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 78 of 116. PageID #: 237684 Highly Confidential - Subject to Further Confidentiality Review | |
|--|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 78 (Pages 306 to 309) | |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 79 of 116. PageID #: 237685 Highly Confidential - Subject to Further Confidentiality Review | |
|--|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| Highly Confidential - Subject to Further Confidentiality | y Review |
|--|-----------------------|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | 80 (Pages 314 to 317) |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_80 of 116. PageID #: 237686

Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 81 of 116. PageID #: 237687

Highly Confidential - Subject to Further Confidentiality Review

Page 318 Page 320 regulatory and law, Patty Zagami, correct? 1 1 name as the gentleman that signed the three letters 2 2 that we went through earlier from the DEA in 2006, A. Her name is listed here too, yes. 3 3 Q. Yes, ma'am. And now if you look above early 2007 and late 2007? that, Anika Madarasz. Can you help me out with A. I don't remember looking at the 4 4 5 5 that? signatures of those letters. 6 A. I vaguely remember her. 6 Q. And if you'd turn the page to Bates 7 7 No. 47, at the top of the page, the fourth bullet Okay. Q. down, "Reviewed 21 CFR 1301.74." Are you there 8 I'm not comfortable correcting your 8 9 pronunciation. 9 with me? Q. All right. And then -- so, that e-mail 10 A. Yes, I see that. 10 11 then is forwarded to several people, correct? Q. And you recognize that language. That 11 A. Yes, she sent this e-mail to a number of 12 was in all of the letters that we reviewed from the 12 13 different people, yes. 13 DEA in 2006 and 2007 about the registrant designing 14 14 and operating "a system to disclose to the Q. And then Mike Bleser sent the e-mail to you, correct? registrant suspicious orders of controlled 15 15 16 A. Me, Denny and Frank. 16 substances." Correct? 17 Q. I might just be tired. But do you see 17 A. That's what this says, yes. 18 Anika, Anika's name anywhere on that e-mail below? Q. And the bullet below, "If suspicious -18 19 A. I do not. 19 you don't ship. Decreasing the order and shipping 20 Q. Do you have any understanding of how 20 is not complying with the regulation." Anika could forward an e-mail that we don't see her 21 21 Did I read that right? 22 A. You read that correctly, yes. copied on? 22 23 A. Someone cut something out. I -- I don't 23 Q. So, we just looked at a Buzzeo 24 know. 24 presentation that you attended in October of 2012 Page 319 Page 321 1 Q. And then Mr. Bleser forwarded the 1 and within a month of the Buzzeo presentation 2 2 contents of the e-mail to you, correct? Mr. Rex Swords is at another meeting with the DEA 3 A. Correct. 3 where he's being told, "Decreasing the order and 4 O. So, let's look back down at Mr. Swords' 4 shipping is not complying with the regulation," 5 5 e-mail to Kermit Crawford, amongst others, and what correct? б I want to direct your attention to is that he's б A. That's what this says, yes. 7 referencing a November 8th DEA meeting at NAPB, 7 And this was sent to you as well, 8 correct? 8 correct? 9 A. That's the subject line, yes. 9 A. It was forwarded on to me, yes. 10 Q. I forget the acronym. National 10 Q. And then the next bullet says, "Ignoring 11 Association of? 11 suspicious orders will result in civil penalties. 12 A. Boards of Pharmacy. 12 Cited Cardinal, ABC and McKesson fines." 13 Q. There you go. 13 Correct? 14 And he relays that "I have the sense 14 A. That's what that statement says, yes. that today's meeting was a condensed version of the 15 15 Q. Now, let's go down to three-quarters of 16 regional meetings the DEA is holding throughout the 16 the page and you see "Red Flags"? 17 country for pharmacists." He references that he 17 A. Yes, I see that. 18 thought several of the chains were there. 18 Q. And at least some of these red flags are 19 Do you see that? 19 the same red flags that were identified in the 20 A. Yes. 20 Buzzeo presentation, correct? 21 Q. But below that, what I want to point A. I believe so. 21 22 out, do you see Joseph Rannazzisi? 22 Q. And this is coming directly from the DEA 23 23 I see his name, yes. to Walgreens, correct? 24 24 MR. SWANSON: Object to form, lacks Yes, ma'am. And do you recognize his

Page 322 Page 324 others. Do you see that? 1 foundation. 1 2 BY THE WITNESS: 2 A. I don't have a copy of the paper yet. 3 3 Q. I'm sorry, Ms. Martin. A. It's coming from an e-mail that Rex 4 wrote 4 (WHEREUPON, a certain document was 5 BY MR. MOUGEY: 5 marked as Walgreens-Martin Exhibit 6 Q. Yes, ma'am. Where he references a 6 No. 29: 8/3/10 e-mail with 7 7 meeting with Joseph Rannazzisi, the Deputy attachments; WAGMDL00660331 -8 Administrator -- Deputy Assistant Administrator, 8 00660337.) 9 Office of Diversion Control, correct? First page, 9 BY MR. MOUGEY: middle of the page. 10 10 Q. Do you have it in front of you, 11 A. Yes. Ms. Martin? 11 12 Q. And he -- Mr. Swords goes on, 12 A. Yes, I do. 13 "Mr. Rannazzisi presented a large PowerPoint deck 13 Q. All right. This is an e-mail from 14 on prescription drug trafficking and abuse for two Daniel Coughlin to yourself, amongst others, dated 14 hours," correct? "Approximately two hours," August 3, 2010, correct? 15 15 16 correct? 16 A. It's to Marcie, and I'm cc'd among 17 17 another bunch of people. A. That's what that says, yes. 18 Q. So, you, your boss, Mr. Bleser, 18 Q. Yes, ma'am. And including Mr. Piñon, 19 Mr. Murray and several senior members of Walgreens 19 correct? 20 management were put on alert that decreasing the 20 A. Yes, I see his name. 21 order and shipping is not complying with the 21 Q. Do you recall who Daniel Coughlin is? 22 22 regulation as of November 9, 2012, correct? A. I know he had something to do with the 23 That's what this document says, yes. 23 distribution centers. I'm not sure of his exact 24 Did Walgreens take the information that 24 title. I want to say vice president. Page 325 Mr. Swords passed around and change its algorithm 1 Q. Do you know if he was in a specific 1 2 2 to no longer cut what it internally was calling a distribution center or was he in corporate? 3 suspicious order? 3 I don't remember where he was based. So, the subject line is "Suspicious 4 MR. SWANSON: Object to form, lacks 4 5 Controlled Drug Orders." 5 foundation. б BY THE WITNESS: б Do you see that? 7 A. I know over the years we have made a lot 7 A. Yes, I see that subject line. of different changes. What we did when is a little 8 8 Q. And he had two questions. Do you see 9 bit vague to me. But I would believe that, yes, we 9 that it's No. 1 and No. 2? 10 did act on this information. 10 A. Yes, I see that. 11 BY MR. MOUGEY: 11 Q. And No. 1, he said, "I recall the old 12 Q. Do you recall that version 5.5, which 12 paper report as being inches thick. This was 13 was entered after these October and 13 replaced by same data on disk and eventually electronic transmission. We were instructed in 14 November e-mails, still included in the algorithm a 14 15 suspicious order being cut and not reported to the 1985 not to review or contact anyone on the data." 15 16 DEA? 16 Did I get that right? 17 MR. SWANSON: Object to form. 17 A. That's what this says, yes. BY THE WITNESS: Q. Okay. "Who from your group has been 18 18 19 A. I don't remember that directly off the 19 reviewing the data collected for the past 25 vears?" 20 top of my head. 20 21 BY MR. MOUGEY: 21 Now, did that give you some pause for 22 Q. Ms. Martin, I want to go back in time to 22 alarm in August 3 of 2010 that Mr. Coughlin was 23 August of 2010. Mark this as Martin 29. This is 23 asking Ms. Ranick in Loss Prevention and copying an e-mail from Daniel Coughlin to yourself, amongst 24 24 you asking who has been reviewing the suspicious

Page 326 Page 328 controlled drug orders for the last 25 years? A. No, it was not me. We didn't have --1 1 2 MR. SWANSON: Object to form, foundation. 2 the program that I worked on didn't exist 25 years 3 3 BY THE WITNESS: ago. 4 A. This e-mail wasn't sent to me. So, I 4 BY MR. MOUGEY: don't know what Marcie or her team was doing and --5 5 Q. At any point in time in your tenure at б BY MR. MOUGEY: 6 Walgreens that we have been discussing today from 7 7 Q. Did you ask? the suspicious order monitoring that you were 8 A. I personally did not. 8 involved in, so, from 2008 to 2012, were you 9 Q. And did you not ask because when you 9 charged with reviewing suspicious controlled drug look at an e-mail like this that you've got Dwayne 10 10 orders to perform due diligence to ensure the 11 viability of those orders going to legitimate Piñon from legal on this that you assumed that 11 regulatory and law was ensuring that Walgreens was 12 patients outside of just testing the validity of 12 13 complying with its obligations as a distributor 13 the reports? 14 under the federal code and the federal regs? 14 MR. SWANSON: Object to form. 15 MR. SWANSON: Object to form. 15 BY THE WITNESS: 16 BY THE WITNESS: 16 A. Yes, I was performing due diligence on 17 A. I was assuming that if this was 17 some of those reports. 18 addressed to Marcie, that her and her team were 18 BY MR. MOUGEY: 19 taking appropriate action. 19 Q. And define for me what you mean by due 20 BY MR. MOUGEY: 20 diligence. 21 Q. 25 years. Who has been reviewing these 21 A. I would look at data. I would look at 22 22 reports for the last 25 years, somebody from the the store's history and see if it made sense. If 23 distribution center, under suspicious drug 23 something didn't make sense to me, I would call the 24 controlled drug orders. That doesn't make you stop 24 store or the district manager or the pharmacy Page 327 Page 329 1 what you're doing for the course of the day and 1 supervisor and try to obtain additional 2 2 follow up? 25 years? information. 3 A. It wasn't my area of responsibility. 3 Q. And that was part of your 4 Q. Did it not give you any concern that a 4 responsibilities in the, you know, a few hours up 5 5 member of Walgreens distribution center is asking to ten hours a week reviewing the reports from the б who has been reviewing our suspicious controlled б algorithm? 7 drug orders for the last 25 years? 7 A. Yes. MR. SWANSON: Object to form. 8 8 Q. Let me hand you Martin 30. 9 BY THE WITNESS: 9 (WHEREUPON, a certain document was 10 A. He's asking a question. We don't know 10 marked as Walgreens-Martin Exhibit 11 based on this e-mail who was or who wasn't doing 11 No. 30: 1/10/11 e-mail string; 12 it. Just because he's asking who doesn't mean it 12 WAGFLDEA00000846 - 00000851.) 13 wasn't being done. 13 BY MR. MOUGEY: 14 BY MR. MOUGEY: 14 Q. This is an e-mail chain with you 15 Q. And it certainly wasn't you, correct? 15 included and Kristine Atwell. Are you familiar 16 A. This reporting was not my area of 16 with Ms. Atwell? 17 responsibility. 17 A. I remember her name, yes. Q. Yes, ma'am. You remember her name from 18 Q. And not just reporting. Reviewing. 18 19 this e-mail exchange? What he is asking is who from the group has been 19 20 reviewing the data collected for the last 25 years, 20 A. Yeah, I remember we had -- she worked in 21 suspicious controlled drug orders. That was not 21 Jupiter. We had a number of different 22 you, correct? 22 conversations via either phone call or e-mails.

She worked at the Jupiter distribution

23

24

Q.

center?

23

24

MR. SWANSON: Object to form.

BY THE WITNESS:

Page 330 Page 332 you're purchasing or returning C-II drugs. 1 Yes. 1 A. 2 2 Q. The one that was padlocked by the DEA, Q. "This is creating an issue in 3 3 correct? maintaining enough 222 forms to fill all of the 4 MR. SWANSON: Object to form. 4 orders because a new 222 form is generated for 5 BY MR. MOUGEY: 5 every 128 bottles of this WIC," and that is the --6 Q. Correct? 6 what's WIC stand for again? 7 7 A. She worked in Jupiter, yes. A. Walgreens item code. 8 Q. Yes, ma'am. The same Jupiter that the 8 Q. -- "that are ordered. For example, when 9 DEA came in and locked up the cage and kept 9 they order 450 bottles, there will be four 222 Walgreens from accessing its Schedule II and forms printed to accommodate this one order. I 10 10 11 Schedule III opiates, correct? feel that this store needs to justify the large 11 12 A. That's in a different time period than 12 quantity." 13 this e-mail. 13 Did I read that right? 14 14 Q. Yes, ma'am. That's not what I asked. That's what she wrote, yes. "Three stores that come to mind are," 15 What I simply asked you was: This is 15 16 the same Jupiter that was ultimately where the 16 and I'm going to -- I want you to help me remember 17 locks were changed by the DEA, correct? these. Write these down. Do you have a pen over 17 18 there? A. Yes. 18 19 Q. And this e-mail chain is dated 19 A. I do not. 20 January 10, 2011, correct? 20 Okay. 7298, 3836 and 5018. Okay. Got 21 A. That is correct. Yes. 21 it? 22 22 O. And if we start at the bottom of this A. I might have to flip back and forth. 23 e-mail chain on Bates No. 51, the very last page, 23 Q. All right. We'll just kind of put this 24 there is two sets of Bates numbers. This is 24 document off to the side. Page 331 Page 333 1 WAGFLDEA851, very last page. 1 So, essentially Ms. Atwell is asking 2 2 A. Yes, I see that. you, these stores should justify these large 3 O. You can see this is an e-mail from 3 amounts of Schedule II controlled substance. 4 Kristine Atwell. 4 correct? 5 5 "What are your thoughts on this matter?" A. Of this particular item, yes. б Do you see that? б Q. Yes, ma'am. And you respond to her on 7 A. I see that, yes. 7 Bates No. 49 and reply, "I am able to look at store 8 8 item movement if this helps." Q. Okay. Let's go to the previous 9 page where Ms. Atwell from the Jupiter distribution 9 Do you see where I am? 10 center asks you, "I have" -- and I'm on Bates 10 A. Yes. No. 50 -- "I have several stores that are ordering "You can contact the store for more 11 11 12 huge quantities of 682971 on a regular basis." 12 information." 13 And that is a controlled substance, 13 So, you didn't contact the store. You 14 told her to contact the store. Correct? correct? 14 15 A. Off the top of my head I don't remember 15 A. That's what I wrote, yes. 16 what that WIC number is associated with, but --16 Q. Somebody in the distribution center, 17 Q. This is -- I'm sorry. Go ahead. Were 17 correct? 18 you finished? 18 A. That's what I wrote, yes. 19 A. We'll just assume it's some kind of a 19 Not Barb Martin performing the due 20 C-II because she is mentioning the 222 forms. 20 diligence. You told her to contact the store, 21 Q. Yes, ma'am. The 222 forms need to be 21 correct? 22 filled out when a certain amount of controlled 22 MR. SWANSON: Object to form. 23 23 BY THE WITNESS: substances are shipped, correct? 24 A. The 222 form is required by the DEA when 24 I told Kristine to reach out to the

Page 334 Page 336 1 1 redo that. store, yes. 2 BY MR. MOUGEY: 2 Ms. Atwell responds to you. That makes 3 3 Q. You said, "These sales are quite high it even better. 4 compared to other non-Florida stores." 4 She runs "a query to see how many 5 Correct? 5 bottles we have sent," and she says, "store 3836," 6 A. That's what I wrote, yes. 6 "and we have shipped them 3271 bottles between 7 7 12/1/10 and 1/10/11." Q. "Store 7298 sells about 22,000 tabs of 8 682971 every week." 8 Now do I have that right? That's from 9 Correct? 9 her to you, correct? MR. SWANSON: Object to the preface. Go ahead 10 A. That's what I wrote, yes. 10 11 "That translates to 220 bottles per 11 and answer. week." 12 BY MR. MOUGEY: 12 13 Is that "SO"? Is that supposed to be 13 Q. That's from her to you, correct? "of"? 14 14 A. Yes, she wrote this e-mail. 15 Oh, I'm sorry. Never mind. 15 Q. So, she runs the query and then she 16 "That translates to 220 dollars per 16 says, "I don't know how they can even house this 17 week, so 450 bottles is more than a two-week 17 many bottles to be honest." 18 supply." (As read.) 18 Correct? Did I get that right? 19 Did I get that right? 19 A. That's what she wrote, yes. 20 A. I wrote "a little more than a two-week 20 "How do we go about checking the 21 supply." 21 validity of these orders?" 22 22 Q. Yes, ma'am. And if you turn to Bates Correct? 23 No. 47, you e-mailed her again and said, "I ran a 23 A. That's what she wrote, yes. 24 query to see how many bottles we have sent to store 24 Here we are, Barb Martin doing due Page 337 1 3836 and we have shipped them 3271 bottles between 1 diligence on the store, gets contacted by the 2 2 distribution center. There is 3271 bottles. The 12/1/10 and 1/10/11." 3 Correct? 3 distribution center is asking you what do we do. 4 MR. SWANSON: Object to form, mischaracterizes 4 And what do you tell her on the first page, the document. 5 5 Ms. Martin? б BY MR. MOUGEY: б Make sure I get this right. This is 7 Q. "I ran a query to see how many bottles 7 from you to her, right? we have sent to store 3836 and we have shipped them 8 You don't make the call. You tell her 8 9 approximately 3271 bottles between 12/1/10 and 9 after 3200 bottles of a Schedule II to one 1/10/11." pharmacy, you tell her, "Terry Collins is the 10 10 11 Did I read that right? 11 district pharmacy supervisor. His cell is," and 12 MR. SWANSON: Same objection. 12 you give her the cell, "He may be able to shed the 13 MR. MOUGEY: What's your objection, Counselor? 13 light on the subject." MR. SWANSON: You said she wrote it. 14 14 Did I get that right? 15 MR. MOUGEY: You're right. These e-mails are 15 A. That's what I wrote, yes. 16 so jacked up. 16 Q. Yes, ma'am. Now, when you were 17 MR. SWANSON: Wasn't hard for me to figure 17 testifying to this jury about the due diligence you 18 18 would perform on orders that would -- that were out. 19 MR. MOUGEY: Yes, because you are so much 19 flagged, is this the kind of due diligence you 20 smarter than me. I appreciate that. You all 20 performed where you told the distribution center remind me of that every day. I will work hard to after they ask you how do we check about the 21 21 get there. 22 22 viability, you tell them to contact the district 23 23 pharmacy supervisor? BY MR. MOUGEY: 24 24 Q. So here you are. I apologize. Let's That is one way of doing it. I can look

Page 338 Page 340 1 at sales history and I can see what was ordered. 1 Suspension to Walgreens Jupiter," and it cites to 2 But I'm not near that store. I don't have access 2 Exhibit B. 3 3 to the prescriptions that they're filling and I Do you see that? 4 don't have access to any of their patient 4 A. I see that, yes. 5 information. 5 Q. Okay. Let's go to Exhibit B. Go to the tab. It says Appendix B. It's dated September 13, 6 That is why I referred her to Terry who 6 7 7 is in the district, and he could go and work with 2012. 8 that store to determine why they're filling so many 8 Do you see that? 9 prescriptions for their patients. 9 A. I see that, yes. 10 Q. That was one day after your e-mail to 10 Q. So, this is the typical type of due 11 your boss informing him that the DEA had changed diligence when you mentioned it earlier, you would 11 the locks on Walgreens' cage, correct? 12 tell the Jupiter distribution center that was 12 13 ultimately locked by the DEA that she should call 13 A. I don't remember the exact dates. 14 the district pharmacy supervisor, correct? 14 This document, Exhibit B, Order to Show MR. SWANSON: Object to form. 15 15 Cause and Immediate Suspension of Registration on 16 BY THE WITNESS: 16 Page No. 28 of 349, correct? 17 A. It's one of the types. Since I didn't 17 Do you see the page numbers in the have access to this store's information, that's -middle of the page, 28 of 349? 18 18 19 I couldn't take any direct action. 19 A. At the bottom, yes. 20 (WHEREUPON, a certain document was 20 Yes, ma'am. And you see the title where 21 marked Walgreens-Martin Exhibit 21 it says Order to Show Cause and Immediate 22 No. 31: Binder of documents, 22 Suspension of Registration, correct? 23 "Settlement and Memorandum of 23 A. Yes. 24 Agreement" and various other 24 And if you look at paragraph 1, it's Page 339 Page 341 1 documents; beginning Bates No. 1 referencing Walgreens Jupiter Florida distribution 2 2 WAGMDL00490963.) center, correct? Paragraph 1. 3 BY MR. MOUGEY: 3 A. Yes. 4 Q. I hand you what we're going to mark as 4 Q. If you look at paragraph 2, the first Martin 31, and I ask you to remember that store 5 sentence, "Since at least 2009, the State of 5 б number. б Florida has been the epicenter of a notorious, 7 So, before we go to Exhibit 31, the 7 well-documented epidemic of prescription drug 8 abuse." 8 store number that she was asking about with the 9 3,200 bottles on Bates No. 47 is 3836. Okay? 9 Did I get that right? 10 Do you see that, 3836? 10 A. That's the statement written here, yes. Q. And follows it up with, "In July of 11 A. I see that, yes. 11 12 O. Martin 21 -- 31 is titled Settlement and 12 2011, the Florida Surgeon General declared a public 13 Memorandum of Agreement, correct? 13 health emergency based on the prescription pill 14 A. That's the title of this document, yes. epidemic which results in an average of seven 14 15 overdose deaths per day in Florida." Q. Yes, ma'am. And if you look at No. 4 on 15 16 Bates No. 63, you'll see that it references 16 Correct? 17 "Walgreens' Jupiter Distribution Center is 17 A. That's what this document says. 18 registered with the DEA as a distributor of 18 Q. The dates in paragraph 2 from 2009 to 19 Schedule II through IV." (As read.) 19 2011 cover the exact same time span when you and 20 Do you see that? Paragraph 4? 20 your colleagues at Walgreens are working on the 21 A. Yes, I see that. 21 suspicious order monitoring policy with Mr. -- with 22 Q. You will see in paragraph 5, "On 22 Mr. Bancroft, correct? 23 September 13, 2012, the DEA by its Administrator 23 Yeah, that sounds right. 24 issued an Order to Show Cause and Immediate 24 If you turn the page to page 30 of 349,

Page 342

Highly Confidential - Subject to Further Confidentiality Review

1 at the top of the page lists six store locations.

2 Do you see those?

5

7

8

3 A. Yes, I see those.

4 Q. And if you look at No. 4, 3836 is the

exact same store that Ms. Atwell was e-mailing you

6 about in the beginning of 2011, correct?

A. That is, yes, one of the stores.

Q. When she relays, "I ran a query to see

9 how many bottles we have sent to store 3836. We've

10 shipped them 3271 bottles from 12/1/10 to 1/10/11.

11 I don't know how they can keep this many bottles to

be" -- "how they can even house this many bottles

13 to be honest. How do we go about checking the

14 validity of these orders?"

15 Correct?

16 A. That's what she wrote, yes.

Q. Yes, ma'am. And if you look at No. 4 on

store 3836, oxycodone is Schedule II and one of the

19 most highly abused controlled substance --

20 controlled substances, correct?

A. By definition, when the DEA classifies a

22 product as a Schedule II, it's both highly

23 addictive and abusable.

Q. And according to these numbers and the

1 agreement with the DEA, Walgreens went from 344,000

dosage units to 849,000 dosage units, correct?

3 MR. SWANSON: Object to form, mischaracterizes

4 the document you're reading from.

5 BY THE WITNESS:

6 A. I see the changes in numbers. Again,

7 I'm just not -- I'm not sure where this data is

8 coming from.

9 BY MR. MOUGEY:

10 Q. I understand. But let's just look --

11 let's do this just to clear up any confusion.

Turn to page 2 of 349 and keep your

thumb in 30 of 49. Do you see "Stipulation and

14 Agreement"?

15 A. I see that title.

Q. What do you understand, Ms. Martin, that

17 "Stipulation and Agreement" means?

A. I'm not really sure. This looks like a

very complicated legal document, and I would leave

it for someone that's more --

Q. Yes, ma'am, like Mr. Piñon to tell us.

Paragraph No. 2, "Walgreens acknowledges

23 that suspicious order reporting for distribution to

24 certain pharmacies did not meet the standards

Page 343

20

1

б

7

10

16

22

e 343

D

Page 344

1 agreement between Walgreens and the DEA in 2009,

2 there were 344,000 dosage units of oxycodone in

3 2009, correct?

4 MR. SWANSON: Object to form, characterization.

5 BY THE WITNESS:

6 A. I'm not sure where this data is being

7 supplied from.

8 BY MR. MOUGEY:

9 Q. Yes, ma'am. Because you certainly

10 didn't go and look. You told her to contact the

11 pharmacy supervisor, correct?

MR. SWANSON: Object to form, argumentative.

13 BY MR. MOUGEY:

16

Q. Because you don't know the numbers,

15 correct? You never looked?

A. For this particular store, if you go

back on my e-mail, I was unable to look because I

was unable to access the store's system. Since I

19 didn't have any other information to justify the

20 information. I referred her to someone that was

21 closer to the store and could have helped her.

Q. While seven people a day in the State of

23 Florida are overdosing, the oxycodone purchases by

dosage unit from 2009 to 2010, according to the

identified by DEA in three letters from DEA Deputy

Assistant Director, Office of Diversion Control,
 sent to every registered manufacturer and

sent to every registered manufacturer anddistributor, including Walgreens, on September 27,

5 2006, February 7, 2007 and December 27, 2007."

Did I get that right?

MR. SWANSON: Object to the preface to that

8 question. Go ahead and answer.

9 BY MR. MOUGEY:

Q. Did I get that right, Ms. Martin?

11 A. I believe you read the words correctly.

Q. Do you recognize those dates as the

13 letters we went through earlier, September of '06,

14 February of '07 and December of '07?

15 A. Vaguely.

Q. Yes, ma'am. And you understand that

17 Walgreens is acknowledging that its suspicious

18 order reporting for the Jupiter distribution center

did not meet the standards identified in those

20 letters?

A. That's the verbiage on this form.

Q. Yes, ma'am. That Walgreens signed and

agreed to, correct, ma'am?

A. I have no direct knowledge of who signed

Page 346 Page 348 community is in store 3836, Port Richey, Florida? 1 it. 1 2 Q. I thought you might say that, so why 2 A. I -- I don't know that area. 3 3 Do you have Google on your computer? don't we turn to page 11 of 349, less than ten I do now. I don't know if I had it back 4 pages after the Stipulation and Agreement wherein 4 5 5 "Walgreens acknowledges that suspicious order then. 6 reporting for distribution to certain pharmacies 6 Q. So, if you would have Googled Fort 7 7 did not meet the standards identified by the DEA," Pierce back then, you would know -- I'm sorry --8 you see that Thomas Sabatino, executive vice 8 Port Richey, you would have looked and found that 9 president, general counsel and corporate secretary, 9 Port Richey, Florida has a population of signed on behalf of Walgreens on June 10, 2013, 10 approximately 5,000 people. 10 11 correct? 11 5,000 people in January '11, over 12 A. I see that, yes. 12 1.4 million dosage units of oxycodone, correct? 13 Q. Yes, ma'am. So let's go back to page 30 13 MR. SWANSON: Object to form, assumes facts 14 of 349 and store 3836. 14 not in evidence, foundation. So, in the data provided in this BY THE WITNESS: 15 15 16 agreement, Walgreens dosage units of oxycodone from 16 A. I'm not sure I understand what you're 17 the store that you were contacted about in 17 trying to ask me. 18 January of '11 went from 344,000 dosage units 18 BY MR. MOUGEY: 19 according to this document to 849,000, correct? 19 Q. Yes, ma'am. If you would have looked in 20 MR. SWANSON: Object to the characterization. 20 January -- at the beginning of January '11, you 21 BY THE WITNESS: 21 would have been able to determine that Port Richey, 22 A. That's what the numbers on the form say. 22 Florida has a population of approximately 5,000 23 BY MR. MOUGEY: 23 people and potentially prevented Walgreens from 24 And you understand that that is an 24 dispensing 1.4 million dosage units in that Page 347 Page 349 1 increase of approximately 150% in the course of 1 community, correct? 2 2 that one year, correct? MR. SWANSON: Object to form. 3 A. I don't -- I wouldn't be able to do 3 BY THE WITNESS: 4 those calculations in the top of my head. 4 A. Again, I'm still not sure what your 5 5 question is. Q. How about this. It's more than double? б 344,000 times 2 is 688,000, right, more than б BY MR. MOUGEY: 7 double? 7 Q. Yes, ma'am. As part of your due diligence, did you even look to see how many people 8 8 A. I'll agree to that, yes. 9 Q. Now, you were contacted by Ms. Atwell 9 lived in this community that you were contacted 10 and asking you to check the validity of those 10 about in January '11 about 3271 bottles coming off 11 orders in the very beginning of 2011, January, 11 the shelves? 12 correct? 12 A. I personally did not --13 A. Got the dates on the e-mail. 13 Q. Yes, ma'am. 14 O. Yes, ma'am. 14 A. -- look at the population. Quite 15 15 frankly, I would think that that would be -- do A. Okay. 16 Q. Very beginning of 2011, correct? 16 more harm than good. 17

17 A. Yes, I see that. 18 Q. And in 2011, the dosage units to this 19 one store that you were contacted by -- about in 20 January, the annual dosage units for just oxycodone 21 were 1.4 million.

22 Do you see that?

24

23 A. I see that number, yes.

Do you have any idea how large the

As a pharmacist, I wouldn't want to turn away a patient just because they didn't live in the same city my store was in. I personally live in

19 20 Chicago and I shop in a store in Park Ridge.

21

So, if I looked at just the population 22 of each city, and I said I can only fill that many 23 prescriptions, I think we would be doing more harm 24 than good to our patient population.

18

Page 350 Page 352 And that's why I referred her to Terry BY MR. MOUGEY: 1 1 2 because he was in the area. He would know what 2 Q. I'm sorry? 3 3 that store is doing and if they had patients that A. I understand what the word means. I'd like to know in what context you're trying to use 4 they were serving from other areas. 4 5 5 Q. So, the fact that when you looked, that 6 849,000 dosage units of oxycodone was given -- was 6 Q. Turn to page 38 of 349 of this same 7 7 being dispensed into a town of 5,000 people would document. Paragraph No. 23. The context that I'm 8 not have caused Barb Martin any alarm in the 8 referring to the use of the word "systemic" is 9 beginning of 2011? 9 "Voluntary dispensing restrictions enacted either 10 MR. SWANSON: Object to form. 10 in anticipation of" -- are you there? 11 11 A. I'm sorry. I guess I'm -- because I BY THE WITNESS: 12 A. I wasn't looking at that data. 12 don't --13 BY MR. MOUGEY: 13 Q. Let's do the bottom --14 14 You said page 48, right? Q. Yes, ma'am, and that's not what I asked, if you looked at it. We've already established you 15 15 The bottom page numbers, 38 of 349. 16 didn't know that there was 5,000 people in that 16 A. I'm sorry. 17 community. What I asked was a little different. 17 38. That's okay. O. 18 If you had looked in the beginning of 18 I turned to 48. 19 2011 and you would have seen that 849,000 dosage 19 O. Paragraph 23. 20 units of oxycodone were being dispensed by 20 A. Okay. I see 23. 21 Walgreens where you had spent almost 25 years at 21 "Voluntary dispensing restrictions 22 22 this point, would that have caused you any alarm? enacted either in anticipation of, or in reaction 23 MR. SWANSON: Object to form. 23 to regulatory action, do not indicate to me that 24 BY THE WITNESS: 24 the Respondent and its parent company have Page 351 Page 353 1 A. I would need to know more history than 1 recognized and adequately reformed the systemic 2 2 just a couple of the numbers on a piece of paper. shortcomings discussed herein." 3 BY MR. MOUGEY: 3 So, in that context, language from the 4 Q. And that's exactly the point of 4 DEA about Walgreens' systemic shortcomings, what 5 does that mean to you, Ms. Martin? 5 performing due diligence, correct, Ms. Martin, is б that you gather information to make an educated б MR. SWANSON: Object on foundation. 7 decision, correct? 7 BY THE WITNESS: A. And if I'm not capable of gathering that 8 8 A. It's not my responsibility to determine 9 information, I find other people that can. 9 what the DEA means. I left that up to our legal 10 Q. So, when you told this jury earlier that 10 department. 11 you were performing due diligence on stores, your 11 BY MR. MOUGEY: 12 realm of expertise, your wheelhouse does not even 12 Q. Sitting here today in 2018, to this 13 include Googling the city where the pharmacy is 13 jury, when I'm asking you what the word "systemic 14 located to see what the population is? 14 shortcoming" means in this document from the DEA, 15 A. Again, I don't see how that's relevant. 15 you don't have the wherewithal or the ability to 16 I wouldn't want to limit patients to only go to 16 tell me what that means? 17 pharmacies in the city they live in. 17 MR. SWANSON: Object to form. 18 Q. Do you understand what the word 18 BY THE WITNESS: 19 "systemic" means, Ms. Martin? 19 A. Again, I'm not comfortable making a 20 A. I guess it depends in what context you 20 legal decision on a legal document. 21 want to use the word. 21 BY MR. MOUGEY: 22 Q. Just systemic. Corporate-wide. Do you 22 Q. I'm asking you to tell us what the 23 understand what "systemic" means? 23 meaning of a word, "systemic," is in a sentence. 24 MR. SWANSON: Object to form. 24 You're not comfortable making that

Page 354 Page 356 look into it and respond if required. 1 determination today? 1 2 MR. SWANSON: Objection; foundation. 2 MR. MOUGEY: That's fine. Thank you. 3 3 MR. SWANSON: Thanks. BY THE WITNESS: A. I'm not comfortable responding on a 4 4 **EXAMINATION** 5 legal document. 5 BY MR. SWANSON: 6 BY MR. MOUGEY: 6 Q. So, Ms. Martin, it's been a long day, 7 7 Q. Yet you're telling this jury that from and I know you're tired; and I promise that I'm not 8 the middle of 2008 until the end of 2012, you were 8 going to take a whole lot more of your time, but I 9 a material participant in developing Walgreens' 9 do have just a few questions that I hope I can ask suspicious order monitoring policies and 10 and you can help clarify some questions that I had 10 11 procedures, correct? 11 from your earlier testimony. A. I was one of a number of people involved 12 Earlier, actually for a good part of the 12 13 with the processes, yes. 13 afternoon today, Mr. Mougey went through several 14 14 documents with you, memoranda, business requirement Q. You were one of a number of people who 15 15 were charged with the objective of identifying and documents, et cetera, that related to the 16 reporting suspicious orders to the DEA, correct? 16 suspicious order monitoring system that you had 17 17 some involvement in working on. A. I thought our objective was more coming up with system enhancements. I wasn't involved 18 Do you recall that generally? 18 19 A. Yes. with the reporting part. 19 20 MR. MOUGEY: Let me take a quick break and let 20 Q. And he focused a lot of his attention on 21 me review what I got left. How much time do we 21 a specific word that was contained in those 22 22 have left? reports, and that was "suspicious orders." Do you 23 THE VIDEOGRAPHER: Got about 27 minutes. 23 remember that? 24 MR. MOUGEY: Thank you. 24 Yes. A. Page 357 1 THE VIDEOGRAPHER: We're going off the record 1 Q. And there were some back-and-forth 2 2 between you and Mr. Mougey over whether that was a at 5:33. 3 (WHEREUPON, a recess was had 3 reference to an actual suspicious order or a 4 from 5:33 to 5:53 p.m.) 4 potential or possible suspicious order. Do you 5 THE VIDEOGRAPHER: We're back on the record at 5 recall that? 6 5:53. б A. Yes. 7 MR. MOUGEY: I don't have any further 7 Q. And can you tell us what your questions other than the issue of the performance 8 understanding of that term "suspicious order" as it 8 9 review. I just wanted a confirmation that if we 9 was used in those business requirement documents are not getting performance reviews in specific referred to? 10 10 11 years, does that mean that they don't exist or that 11 A. Even though the document didn't use the 12 there is no reference to opiate-related performance 12 word "potentially," that was what my belief was, 13 in that review. 13 that we were looking for orders that had the 14 So, subject to that answer, because I 14 potential to be suspicious. But until we did more 15 believe we're supposed to be receiving them prior, 15 evaluations of those orders, we weren't sure 16 72 hours prior to the depos, that's the only 16 whether they were suspicious or not. 17 caveat. I don't have any questions and don't 17 Q. And he pulled out or he showed you 18 anticipate a problem, but I would just appreciate during the course of the day a couple of different 18 19 an answer. 19 reports, and I'd like to ask you about those now. 20 MR. SWANSON: Okay. So I don't have an answer 20 The first is, was marked Martin 21 right now, as I told you. You understand. My 21 Exhibit No. 2. Could you pull that out, please. 22 understanding is we have tried to answer that 22 A. Here I have it. 23 question for you. If it hasn't been done to your 23 Q. Okay. And is Martin Exhibit No. 2 one 24 satisfaction, I can't speak to that but we will 24 of the reports that was generated by the system

Page 358 Page 360 that you were asked questions about today? 1 1 a suspicious order? 2 2 A. I do not consider this order to be A. Yes. 3 3 suspicious either. While the suggested quantity, Q. And if you look, it's a document dated August 25 of 2009, right? 4 4 the system order was zero, there was an order by a 5 A. Correct. 5 store user with a user ID of Zulic that ordered a 6 Q. And in the top right corner, it says 6 quantity of 2. This is equal to the tolerance 7 "Suspicious Order," right? 7 limit, so I would not consider this suspicious. 8 A. Right. That's the name that we were 8 They could have been punching this order 9 using. 9 manually for a number of different reasons. The first one that would come to my mind would be the 10 Q. Okay. And as you review Martin 10 11 Exhibit 2, is this a document that you -- well, let fact that it's possible without seeing any other 11 me ask you first a prefatory question. 12 different information that this store never had an 12 13 Was this a document, Martin 2, a 13 order history in the past. If they hadn't had it 14 document that was flagged by the system for you to 14 before and a new patient presented a prescription, 15 review? 15 the system wouldn't know to order it. They would 16 A. This item was flagged, yes. 16 have to order it manually. 17 If you look at Martin Exhibit 2, do you 17 Q. So, even though Martin Exhibit 20 was a 18 consider this to be a suspicious order as you 18 report that was flagged by the system marked as a 19 understand that term? 19 suspicious order, you don't consider this to be in 20 A. I do not consider this to be a 20 fact a suspicious order? 21 suspicious order. My reasoning for that is that 21 A. I do not think this is a suspicious 22 22 the suggested order quantity and the ordered order. 23 quantity are both 3. So, there was no changes that 23 Q. Was it flagged as a potential suspicious 24 the store made from what our system wanted to 24 order? Page 359 Page 361 1 order. And then that number 3 is well below the 1 A. It was flagged for our review, which is 2 2 tolerance limit of 5. why I kept using the term "potentially suspicious." 3 Q. So, even though Martin Exhibit 2 was a 3 MR. SWANSON: Thank you. That clarified it 4 report that was flagged by the system, it said 4 for me. I don't have any more questions. 5 5 "Suspicious Order" on it, you don't consider this MR. MOUGEY: I have a couple follow-up б to be a suspicious order? б questions, Ms. Martin. 7 A. No. 7 **FURTHER EXAMINATION** 8 BY MR. MOUGEY: 8 Q. And then the only other document he 9 showed you a report that he showed you was Martin 9 Q. So, how many years did you review these reports? 10 Exhibit 20. Can you pull that one out, please. 10 11 Might be faster if I just look on the 11 Somewhere between 2 and 4. 12 12 O. Somewhere between 2 and 4. So, screen. 13 Q. Okay. That's fine. Thank you. 13 beginning of 2009 to late 2012, right? 14 This is another report that Mr. Mougey 14 A. Middle 2012 when the Rx Integrity team 15 showed you, again, with a title or a -- the words 15 came and there were various iterations of this form 16 on there "Suspicious Order." 16 as well. 17 Do you see that in the upper right 17 Q. Now, what was produced out of your file 18 was about 22 or 23 of these suspicious order corner? 18 19 reports. Do you have any idea why you had 22 or 23 A. Yes. 19 20 Q. And was this a report that was flagged 20 of these reports isolated? 21 by the system that Mr. Mougey asked you about 21 A. I have no idea why I chose to kept 22 today? 22 those. 23 23 A. Yes. Q. You just happened to keep 22 or 23 of 24 24 Do you consider Martin Exhibit 20 to be these reports?

| H | lighly Confidential | - Subject to Furt | ther Confidentiality | Review |
|-------------|---------------------|-------------------|----------------------|--------|
| REDACTED | | | | |
| TEDITE I ED | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_92 of 116. PageID #: 237698

| C | Case: 1:17-m | d-02804-DA | P Doc#: 1 | .981-7 File | d: 07/24/19 Further Co | 93 of 116. | PageID #: 23 | 37699 |
|----|--------------|------------|-----------|-------------|-------------------------|------------|--------------|-------|
| RE | DACTE | ED | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| REDACTED | | Highly Confiden | tial - Subject | to Further | Confidentiality Review | |
|----------|------------|-----------------|----------------|------------|------------------------|--|
| | REDACTE | D | | | | |
| | ILDIIC I L | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_94 of 116. PageID #: 237700

| REDACTED | | Highly | Confidential - | Subject t | o Further | Confidentiality | Review |
|----------|---------|-----------|----------------|-----------|-----------|-----------------|--------|
| | REDACTE | ED | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_95_of 116. PageID #: 237701

Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 96 of 116. PageID #: 237702 Highly Confidential - Subject to Further Confidentiality Review REDACTED

| Case: 1:17-md-02804-DA Highly Con | AP Doc #: 1981-7 Filed: 07/24 fidential - Subject to Further | 4/19 97 of 116. PageID #: 237703 r Confidentiality Review |
|-----------------------------------|--|---|
| REDACTED | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | Golkow Litigation Services - | 877.370.DEPS |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 98 of 116. PageID #: 237704 Highly Confidential - Subject to Further Confidentiality Review | |
|--|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| | Highly | Confidential - | Subject | to Further | Confidentiality | Review | |
|----------|--------|----------------|---------|------------|-----------------|--------|--|
| REDACTE | D | | | | | | |
| REDITOTE | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_99 of 116. PageID #: 237705

| Case: 1:17-md-(| 02804-DAP Doc#: | 1981-7 Filed: (L - Subject to Fu | 07/24/19 100 of 1 | 16. PageID #: 237 | 7706 |
|-----------------|-----------------|--|-------------------|-------------------|------|
| REDACTED | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| С | ase: 1:17-md- | 02804-DAP Highly Confi | Doc #: 1981 dential - Su | -7 Filed: 07 | / <mark>24/19 101 of</mark> her Confident | 116. PageID # iality Review | #: 237707 |
|-----|---------------|---------------------------|-----------------------------|--------------|--|-----------------------------|------------------|
| RED | PACTED | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| Case: 1:17-mo | d-02804-DAP Doc# Highly Confidentia | t: 1981-7 Filed: (| 07/24/19 102 of 1 | 16. PageID #: 237 | 708 |
|---------------|--|--------------------|--------------------|-------------------|-----|
| REDACTEI |) | ir - Subject to Fi | irther confidentia | IICA WeAlem | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| | Case: 1:17-n | nd-02804-DA Highly Con | P Doc #: 19 | 981-7 Filed: Subject to | 07/24/19 1 Further Conf | LO3 of 116. Fidentiality | PageID #: 237 | 709 |
|----|--------------|---------------------------|-------------|----------------------------|-------------------------|--------------------------|---------------|-----|
| RE | DACTE | D | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| Ca | ase: 1:17-md | -02804-DA Highly Con | P Doc #: 19 | 981-7 Filed Subject to | : 07/24/19 Further Co | 104 of 116 | 6. PageID #: | 237710 | |
|------|--------------|-------------------------|-------------|---------------------------|-----------------------|------------|--------------|--------|--|
| RED. | ACTED | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

| Case: 1:17-md-02804 | 4-DAP Doc #: 1981-7 y Confidential - Subj | 7 Filed: 07/24/19 10 ject to Further Confi | 05 of 116. PageID #3 | 237711 |
|---------------------|--|--|----------------------|--------|
| REDACTED | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| | | Highly | Confidential - | Subject | to Further | Confidentiality | Review |
|---|---------|--------|----------------|---------|------------|-----------------|--------|
| ĺ | REDACTE | D | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_106 of 116. PageID #: 237712

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 107 of 116. PageID #: 237713 Highly Confidential - Subject to Further Confidentiality Review | |
|---|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 108 of 116. PageID #: 237714 Highly Confidential - Subject to Further Confidentiality Review |
|--|
| REDACTED |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

| | Case: 1 | 1:17-md- | 02804- Highly | DAP Do | oc #: 198 | 31-7 File Subject t | d: 07/24/ o Further | 19 109 o | f 116. Pa tiality Re | geID #: 23 | 37715 |
|----|---------|----------|----------------------|--------|-----------|------------------------|------------------------|----------|--------------------------------|------------|-------|
| RI | EDAC | CTED | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 110 of 116. PageID #: 237716 Highly Confidential - Subject to Further Confidentiality Review | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|
| REDACTED | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Golkow Litigation Services - 877.370.DEPS | | | | | | | | | | |

| | Highly Confidentia | al - Subject | to Further | Confidentiality | Review |
|----------|--------------------|--------------|------------|-----------------|--------|
| REDACTED | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

Case: 1:17-md-02804-DAP_Doc #: 1981-7_Filed: 07/24/19_111 of 116. PageID #: 237717

Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 112 of 116. PageID #: 237718
Highly Confidential - Subject to Further Confidentiality Review REDACTED

| Case: 1:17-md-02804-DAP Doc #: 1981-7 Filed: 07/24/19 113 of 116. PageID #: 237719 Highly Confidential - Subject to Further Confidentiality Review | |
|---|--|
| REDACTED | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| C | Case: | 1:17-md- | - <mark>02804-DA</mark> Highly Cor | P Doc#: nfidential | 1981-7 F | iled: 07/2 t to Furth | 4/19 11 4 er Confid | of 116. entiality | PageID #: Review | 237720 |
|----|-------|----------|---------------------------------------|--------------------|----------|--------------------------|----------------------------|----------------------|------------------|--------|
| RE | DA | CTEI |) | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

Golkow Litigation Services - 877.370.DEPS

| Cas | se: 1:17-md- | -02804-DAP Highly Conf | Doc #: 19 | 81-7 Filed: | 07/24/19 Further Con | 115 of 116. fidentiality | PageID #: 23 | 7721 |
|------|--------------|---------------------------|-----------|-------------|----------------------|--------------------------|--------------|------|
| REDA | ACTEL |) | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| | Case: 1:17-m | nd-02804-DAF | Doc #: 198 | 1-7 Filed: 07 | /24/19 116 of 1 | L16. PageID #: 2 | 237722 |
|---|---------------|--------------|------------|---------------|-----------------|------------------|--------|
| R | EDACTE | Z D | | | | 22207 10072011 | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| ۰ | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |